Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 30, 2006 Brian Lawler	Not Bad, Bayer The company's buyout of fellow German firm Schering AG looks like a boon to its bottom line. Investors, take note.
The Motley Fool November 4, 2009 Brian Orelli	An Ode to Schering-Plough Mergers and acquisitions in the pharmaceutical industry are cataloged in a poem.
The Motley Fool September 1, 2009 Brian Orelli	Merck to Bride: Leave the Jewelry at Home The new Merck will look a lot like the old Merck at the top, even though about 40% of Schering's senior leaders will be headed to the new company.
The Motley Fool May 28, 2008 Brian Lawler	A Strange Novartis MS Drug Story Novartis gets approval for a drug with an interesting history.
The Motley Fool July 24, 2007 Brian Orelli	No Pharma Love for Schering A doubling of earnings, but no jump in stock price? Schering investors, take note.
The Motley Fool July 21, 2009 Brian Orelli	Merck and Schering: A Less Ugly Bride and Groom Merck and Schering-Plough are up today on "better than expected" earnings, but the bride and groom don't look all that great heading into the wedding.
The Motley Fool July 30, 2009 Brian Orelli	Merck, Sanofi, and Schering's Love Triangle Perhaps the most complicated deal of the year.
The Motley Fool September 5, 2006 Brian Gorman	Bayer Rising? Bayer still has some hoops to jump through before it's in tip-top shape, but the company has some tantalizing opportunities. Investors, it's not too early to put the German conglomerate on the watch list.
The Motley Fool August 14, 2009 Brian Orelli	The Schizophrenic Drug Approval Schering's drug gets a thumbs-up.
The Motley Fool September 21, 2006 Brian Lawler	Sayonara, Serono The tiny, struggling drugmaker succumbs to a surprise buyout by German pharmaceutical company Merck KGaA. Investors, take note.
The Motley Fool August 29, 2006 S.J. Caplan	Bayer's Crop Headache The company's second-quarter earnings are up while crops drag. Investors, take note.
The Motley Fool January 25, 2005 Stephen D. Simpson	Schering-Plough Turning a Corner The troubled pharmaceutical company begins to show signs of life. Investors looking for a more stable play would do well to look at other shares instead.
Chemistry World May 9, 2014 Andy Extance	Bayer wins race to buy Merck & Co consumer care Germany's Bayer has won a bidding contest for US giant Merck & Co's consumer care business unit, seemingly thanks to a heart drug collaboration sweetener.
Pharmaceutical Executive November 1, 2006 Patrick Clinton	Man in a Hurry Bureaucratic? Bayer? Not if you ask Arthur Higgins. In just over two years, the head of Bayer HealthCare has proved that pharma can be a quick and nimble business.
The Motley Fool August 7, 2007 Brian Orelli	Financing Your Acquisition Schering-Plough is one step closer to financing its $14 billion acquisition of the Organon BioSciences unit of Akzo Nobel, by making an official stock offering.
The Motley Fool May 18, 2009 Brian Orelli	Onyx Cries, "Et Tu, Brute?" The company is suing for the rights to a drug that marketing partner Bayer is developing.
The Motley Fool September 22, 2008 Brian Orelli	Let's Bail Out Pharma Next Schering-Plough is cutting jobs. Maybe the government should help out?
The Motley Fool February 26, 2009 Robert Steyer	Merck KGaA's Good Chemistry This German conglomerate successfully mixes drugs and chemicals.
BusinessWeek October 2, 2006 Gene G. Marcial	Shopping For Schering? The buzz about Schering-Plough on Wall Street is that the company is in play.
The Motley Fool February 27, 2006 Rich Smith	1,001 Teutonic Nights, Part 4 Investors, get to know Germany: Fresenius Medical Care... Altana... Schering...
The Motley Fool October 16, 2006 Brian Lawler	Bayer's Big Drug Boo-Boo The company's forgetfulness could end up hurting its reputation even worse than its revenues.
The Motley Fool August 17, 2009 Brian Orelli	Preparing for a Home Run Some good news and bad news for companies selling drugs to treat multiple sclerosis, after Novartis announces Extavia has been approved by the FDA.
The Motley Fool August 28, 2008 Brian Orelli	Schering and Pfizer Aren't Horsing Around Schering sells some animal health products to Pfizer to keep the EU happy.
The Motley Fool February 13, 2008 Brian Orelli	Schering-Plough Has No Love for the Media Apart from the press bashing regarding the company's cholesterol-lowering drug Enhance, Schering reported a pretty nice quarter.
The Motley Fool July 30, 2010 Brian Orelli	It's Hard to Get Excited About 92% Revenue Growth Especially when revenue dropped on a comparable basis.
The Motley Fool November 29, 2010 Brian Orelli	There's Still Only One Merck KGaA's oral MS drug delay is Novartis' gain.
The Motley Fool April 4, 2008 Brian Orelli	Why Is Schering Cutting Now? The latest pharmaceutical company to jump on the cost-cutting bandwagon is Schering-Plough.
The Motley Fool April 21, 2009 Brian Orelli	Schering and Merck: A Match Made in Purgatory Until Merck can show that it's capable of growing sales again, investors should be leery of stepping in, even with the dividend yield pushing 6%.
The Motley Fool April 6, 2011 Brian Orelli	Merck Inspired to Eye Growth A bolt-on acquisition of eye-care specialist Inspire.
Chemistry World June 22, 2007 Ned Stafford	Big Pharma Not Interested in 'Male Pill' German drug giant Bayer has officially stopped research and development of a hormonal male contraceptive, yet another sign that the pharma industry has lost interest in developing the so-called 'male pill.'
The Motley Fool November 25, 2009 Brian Orelli	A Schizophrenic Move by Merck? Issue $29 billion in shares, buy back $3 billion. Say what? Merck increased its share count by almost 45% to pay for the acquisition of Schering-Plough. Now it's planning to buy some of that stock back.
The Motley Fool October 23, 2007 Brian Orelli	Schering Ploughed Down Investors punish the pharmaceutical company when it misses Wall Street expectations following 11 consecutive quarters of double-digit sales growth.
The Motley Fool October 23, 2006 Brian Lawler	The New Schering-Plough Possibly the cheapest large-cap pharmaceutical company compared with its growth potential, the new Schering-Plough is no dirt. Investors craving only one domestic large-cap pharma stock might be happiest with the new Schering.
The Motley Fool July 29, 2009 Brian Orelli	Ignore These Companies at Your Peril You may not want to invest in them, but don't ignore them.
BusinessWeek April 15, 2010 Naomi Kresge	As the Pill Turns 50, a Rivalry Heats Up With underserved markets in Asia beckoning, Teva is taking on Bayer, the leader in oral contraceptives
The Motley Fool March 3, 2011 Brian Orelli	3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year.
The Motley Fool November 29, 2004 Brian Gorman	Glass Half Full for Bayer Bayer is battling drug recall demons, but the company's positives seem to outweigh its negatives. The German drug and chemical giant posted a net profit of $42 million, reversing a massive loss recorded in the same period last year.
The Motley Fool July 24, 2007 Brian Lawler	Schering Doesn't Slow Schering-Plough continues its strong sales and earnings growth, but it has a big acquisition to digest in coming quarters.
The Motley Fool December 26, 2007 Brian Orelli	Inflamed Anti-Inflammatory Contract Revised J&J and Schering revise their agreement over anti-TNF compounds.
The Motley Fool March 9, 2009 Brian Orelli	Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth.
The Motley Fool March 18, 2009 Brian Orelli	Merck Pummels Pfizer One of these acquisitions is not like the other.
The Motley Fool April 24, 2008 Brian Orelli	Is Schering-Plough the Comeback Kid? Schering posts an OK quarter despite the slowdown in sales of its cholesterol drugs.
Chemistry World August 24, 2012 Andrew Turley	Merck KGaA buys cell culture company Merck KGaA has struck a deal to buy German company Biochrom, which makes cell culture media and buffer solutions, for an undisclosed price.
Chemistry World July 5, 2012	Bayer buys crop protection firm for $425m German chemical and healthcare giant Bayer has struck a deal to buy US firm AgraQuest, which makes pest control products based on 'natural' or specially bred microorganisms.
The Motley Fool November 25, 2008 Brian Orelli	Schering's Peacock Imitation The company lays out its pipeline for investors to see; there are some potential blockbusters waiting there.
The Motley Fool May 21, 2009 Brian Orelli	Not So Fast, Schering ... er, Merck ... er, Whoever You Are Merck got cute with its acquisition of Schering-Plough by setting up the merger so that Schering is technically merging with Merck and then changing its name to Merck. That seemingly schizophrenic move had a purpose.
Chemistry World September 23, 2014 Andy Extance	Bayer to sever polymer arm The German chemical giant has announced plans to spin off its MaterialScience business as a new company within 12 -- 18 months.
The Motley Fool June 30, 2009 Brian Orelli	Johnson & Johnson Inflames Abbott $1.67 billion is one hefty reward.
The Motley Fool February 22, 2006 Rich Smith	1001 Teutonic Nights, Part 2 Investors, get to know Germany: BASF... Bayer... SGL Carbon... Pfeiffer Vacuum...
Chemistry World September 6, 2012 Andrew Turley	Merck KGaA to cut 1100 German jobs Merck KGaA has announced plans to cut 1100 jobs in Germany -- a 10% reduction in its German workforce. The job cuts will be made by the end of 2015, 'in a socially acceptable manner.